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Abstract
Glandular dysplasia in Barrett’s esophagus may re-
gress spontaneously but can also progress to cancer.
The human telomerase RNA template and the human
telomerase reverse transcriptase enzyme which do not,
of themselves, correlate strongly with telomerase
activity, are too often overexpressed in Barrett’s
dysplasia to predict individual cancer risk. This study
relates telomerase activity, mucosal phenotype, and
dysplasia in Barrett’s esophagus. Biopsies (n = 256)
from squamous esophagus, columnar-lined esopha-
gus every 2 cm, esophago-gastric junction, gastric
body, and antrum from 32 patients with long-segment
Barrett’s esophagus were evaluated by telomerase
repeat assay protocol (TRAP). Three biopsies for
histology (n = 794) were simultaneously taken at each
anatomical level. These and all prior and subsequent
biopsies (n = 1917) were reviewed for mucosal
phenotypes and dysplasia severity. Intestinal-type
Barrett’s mucosa was present at all levels in Barrett’s
esophagus. At least one Barrett’s biopsy was TRAP+
in 22 of 32 patients. TRAP positivity of intestinal-type
Barrett’s mucosa increased distally, possibly as a
consequence of mucosal exposure to acid or bile
reflux. Native gastric mucosa was rarely TRAP+ (1/31
corpus, 2/32 antrum), whereas native squamous
mucosa usually was TRAP+ (31/32). Dysplasia al-
most always involved intestinal-type Barrett’s mu-
cosa (85/87; P < .00001), without evidence of
proximal–distal zoning. TRAP could be positive
without dysplasia and negative in extensive, even
high-grade, dysplasia. TRAP activity merits evaluation
as a candidate biomarker for increased risk of per-
sistent dysplasia and cancer progression in Barrett’s
esophagus.
Neoplasia (2004) 6, 85–92
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Introduction
Glandular metaplasia or Barrett’s esophagus is present in
about 10% of adult gastro-esophageal reflux patients, with
progression to invasive esophageal adenocarcinoma in
0.5% to 1% of patients per annum [1]. As few patients
survive symptomatic esophageal adenocarcinoma [2], man-
agement of Barrett’s esophagus aims to detect early pro-
gression to cancer, which may occur despite acid suppression
and control of reflux.
Many gastroenterologists adopt endoscopic and biopsy
surveillance to detect progression from metaplasia through
low-grade to high-grade dysplasia, which is usually associated
with high rates of progression to invasive adenocarcinoma [3],
especially when widespread [4]. However, the benefits are
debated [5]. Not all gastroenterologists think the cancer risk
in Barrett’s esophagus justifies regular endoscopy and biopsy,
and many elderly patients are not fit for esophagectomy [6,7].
On the other hand, surveillance-detected cancer has a better
prognosis than symptomatic cancer [8,9], and mucosal treat-
ments may control high-grade dysplasia and intramucosal
carcinoma in patients unfit for surgery [10].
Although accepted as the most reliable available predictor
of cancer risk, histological diagnosis of dysplasia is challeng-
ing [2,11], and even high-grade Barrett’s dysplasia may be
less aggressive than usually thought. In the Hines VA Hospital
study [12], only 12 of 63 high-grade dysplasia patients fol-
lowed for a mean of 7.3 years progressed to invasive cancer
after prevalent cancer had been excluded by intensive biopsy
during the year following initial diagnosis. Such data highlight
the absence of effective biomarkers of cancer risk in Barrett’s
esophagus [13].
The enzyme, telomerase, has recently received attention as
a marker expressed at high frequency across the whole
spectrum of tumor types [14]. Telomerase is a ribonucleopro-
tein reverse transcriptase involved in the maintenance of
chromosomal telomeres. It allows cancer cells to bypass
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cellular senescence and acquire cellular immortality. Over-
expression of the human telomerase RNA template (hTR) is
frequent in squamous and glandular esophageal carcinomas
[15], and increasing hTR expression from Barrett’s metapla-
sia through low-grade to high-grade dysplasia and Barrett’s
adenocarcinoma has been described [16]. Lord et al. [17]
reported increasing expression of mRNA for human telomer-
ase reverse transcriptase enzyme (hTERT) through Barrett’s
mucosa and dysplasias. Telomerase is, therefore, of interest
for its possible role in facilitating esophageal tumor progres-
sion, its potential as a predictive biomarker, and as a target
for therapy [14], but a full picture of telomerase activity and
cellular senescence in the esophagus has not yet emerged.
Appropriate samples in a well-characterized pathological
and clinical context are critical to the evaluation of new
molecular markers. These are available to our group, which
also has experience in telomerase research [18–23] and
esophageal carcinogenesis [15,24,25]. Because most
patients with Barrett’s dysplasia do not develop cancer, the
finding of relatively ubiquitous expression of hTR and hTERT
in Barrett’s dysplasia suggests that their predictive power will
be limited. However, measurements of hTR or hTERT
mRNA or protein levels do not actually measure telomerase
activity. We therefore undertook a survey of mucosal telo-
merase activity in patients with Barrett’s esophagus to eval-
uate actual telomerase activity as a possible biomarker of
cancer risk in Barrett’s esophagus.
Patients and Methods
Patients
Thirty-two consecutive patients with biopsy-proven long-
segment Barrett’s esophagus attending Glasgow Royal In-
firmary were recruited over a 10-week period. Apart from five
newly diagnosed patients, all were already undergoing at
least annual endoscopy and biopsy, with three biopsies
being taken for every 2 cm of columnar-lined esophagus
(every 1 cm in patients with a previous diagnosis of dyspla-
sia). Patients with previously diagnosed invasive adenocar-
cinoma were not included. In all, the 32 patients had
experienced 152 endoscopies with biopsy, including 77
before the 32 study endoscopies, and 43 after. All patients
had more than 3 cm of columnar mucosa in the distal tubular
esophagus. Median length of Barrett’s esophagus was 8 cm
(range 3–16 cm). Mean and median age of patients at
the time of the study endoscopy was 64 and 70 years
(range 37–84), respectively. There were 24 males and
8 females. Dysplasia was identified in at least one biopsy
in 10 of these patients, and indefinite changes not amounting
to confirmed dysplasia in a further seven. The study was
approved by the Glasgow Royal Infirmary Research Ethics
Committee and patients gave written informed agreement to
participate.
Biopsy Protocol
At the telomerase study endoscopy, three biopsies were
taken for histology from the following locations: original
squamous mucosa proximal to the Barrett’s segment, co-
lumnar side of the squamo-columnar junction (Z line), Bar-
rett’s segment every 2 cm, anatomical esophago-gastric
(EG) junction (defined by the most proximal gastric folds),
gastric corpus, and antrum. Figure 1 illustrates the anatomy
of Barrett’s esophagus and the biopsy sites. All biopsies for
diagnostic histology were fixed overnight in 4% neutral
buffered formaldehyde and embedded in paraffin wax, and
4-mm sections cut at three histological levels. Dewaxed
sections were stained with hematoxylin–eosin. A fourth
biopsy taken at each anatomical level for telomerase (telo-
merase repeat assay protocol, or TRAP) assay was imme-
diately snap-frozen in liquid nitrogen. From these study
endoscopies, a total of 256 individual biopsies was examined
for telomerase activity (median 8, range 6–11 per patient)
and three biopsies from 268 sites (n = 794) were examined
histologically. In addition, histological review was performed
of all esophageal and gastric sites previously (n = 488) and
subsequently (n = 401) biopsied, representing 1057 sites
and 3171 individual mucosal biopsies.
Biopsy Review
The same pathologist with an interest in Barrett’s esoph-
agus (J.J.G.) was responsible for initial reporting of all
biopsies from all endoscopies. Subsequently, all biopsies
Figure 1. Anatomy of Barrett’s esophagus and stomach, with biopsy sites.
Proximal esophagus is lined by its native squamous epithelium. Distal to the
‘‘Z line,’’ this is replaced by characteristic glandular Barrett’s mucosa. Z line is
often irregular and there may be residual islands of squamous epithelium
below it. Anatomical esophago-gastric (EG) junction is taken as the most
proximal extension of the mucosal folds (rugae). Gastric biopsy sites are
indicated in the body (proximally) and antrum (distally).
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were reviewed by the same pathologist ‘‘blind’’ to the original
report. Presence or absence of the following mucosal types
was recorded for each biopsy: 1 = full-thickness squamous
epithelium; 2 = immature squamous ‘‘islands’’ overlying
glandular mucosa; 3 = ‘‘specialized’’ Barrett’s mucosa, de-
fined by goblet cells; 4 = mucosa resembling gastric cardia,
without goblet cells or oxyntic cells; 5 = cardio-oxyntic
mucosa with oxyntic cells, or fully developed gastric fundic
mucosa; 6 = antral mucosa (in gastric biopsies). Intestinal
metaplasia in biopsies from gastric sites was separately
recorded.
Glandular dysplasia was evaluated using published crite-
ria [7,26] in conformity with the Vienna classification [27,28]
in the following groups: 1 = no dysplasia; 2 = mild changes,
possibly reactive: indefinite for dysplasia; 3 = definite dys-
plasia of mild or moderate severity: low-grade dysplasia; 4 =
severe dysplasia/adenocarcinoma in situ: high-grade dys-
plasia. Although this category may also include biopsies in
which invasion is suspected, our series did not include such
biopsies. Phenotype of the dysplastic mucosa and biopsy
level were also recorded.
Published studies show good interobserver and intraob-
server agreement in recognizing high-grade glandular dys-
plasia in Barrett’s esophagus [11,29], but less robust
discrimination between no dysplasia, indefinite for dysplasia,
and low-grade dysplasia. To evaluate the observer’s consis-
tency of dysplasia grading in this study, all biopsies were
rescored ‘‘blind’’ to the original reading, after a minimum
delay of 6 months. The review dysplasia coding was com-
pared with the grading originally assigned. If these were in
agreement, that grading was accepted. If discrepant, a third
‘‘blind’’ review was undertaken before the final allocation of
dysplasia grade was based on the majority reading. Repro-
ducibility of dysplasia grading was evaluated by comparison
of the first and second overall readings for each biopsy group
from a specific site. Although application of diagnostic criteria
has been reviewed with histopathologist colleagues in the
same and other institutions, interobserver agreement was
not evaluated formally.
Derived Calculations and Statistical Analysis
The spatial distribution of mucosal phenotypes in Barrett’s
esophagus was examined by graphing the percentage of
biopsy groups in which each mucosal phenotype was pres-
ent as a function of the distance from the Z line to the
anatomical esophago-gastric junction. The distance along
each Barrett’s esophagus was also expressed as a percent-
age to compensate for the variable length of Barrett’s esoph-
agus in different patients. This was done by mapping the
percentage of biopsies in which a particular mucosal type
was present in each centimeter of a particular Barrett’s
esophagus to the corresponding section of the graph, and
averaged for all 32 patients. The mean percentage was
calculated for every length centile by summation (S) over
all 32 patients as S(100 n1 / L) / S(100 n2 / L), where n1 is the
number of biopsy groups containing the feature in question,
n2 is the total number of biopsy groups, and L is the length of
each Barrett’s esophagus in centimeters. This strategy gives
equal weight to all biopsies. Zonal distribution of dysplasia
was examined identically, taking n1 as the number of biopsy
sites found to be dysplastic, and n2 as the number of sites in
which ‘‘specialized’’ Barrett’s mucosa was confirmed (be-
cause dysplasia was almost exclusively associated with the
intestinal phenotype). Zonal distribution of telomerase activ-
ity was mapped analogously.
The j statistic [30] was calculated as a measure of
agreement using Analyse-It version 1.48 (Analyse-It Co.,
Leeds, UK) in Microsoft Excel ’97. Group comparisons were
made using Fisher’s exact test.
TRAP Assay
Telomerase activity of biopsy samples was determined
by a modification of the telomeric repeat amplification pro-
tocol described by Kim and Wu [31]. Figure 2 shows repre-
sentative analysis results. Biopsy samples were lysed with
200 ml of TRAP lysis buffer, as described [32]. Ten microliters
of appropriately diluted extracts (containing 2 and 0.2 mg of
protein extract of each sample) was added to 40 ml of
elongation buffer [50 mM dNTPs, 1mg of telomerase sub-
strate primer (5V-AATCCGTCGAGCAGAGTT-3V), 20 mM
Tris/HCl, pH 8.3, 1.5 mM MgCl2, 63 mM KCl, 1 mM EGTA,
and 0.1 mg/ml BSA]. Samples were incubated at room
temperature for 30 minutes to allow telomerase-mediated
extension of the substrate primer. Endogenous nonspecific
inhibitors of Taq DNA polymerase and, consequently, poly-
merase chain reaction (PCR) [33] can be removed by
purification of the extension product prior to PCR. Accord-
ingly, the extension product was purified with QIAquick
Nucleotide Removal Kit (Qiagen, Crawley, West Sussex,
UK) according to the manufacturer’s protocol and eluted
from the spin column in 40 ml of dH2O. Eluted product was
Figure 2. Example of TRAP assay. Lane 1 = molecular weight (MW)
markers. In lanes 2 to 4, 5 to 7, and 8 to 10, the first and second lanes
represent analysis of 2 or 0.2 g of protein extract, whereas the third lane is a
heat-inactivated control. BM = Barrett’s mucosa. Lanes 2 to 4 = Barrett’s
mucosa at 34 cm. Lanes 5 to 7 = Barrett’s mucosa at 35 cm. Lanes 8 to 10 =
gastric body mucosa. Lane 11 is a positive control (C+; GLC4 cells) and lane
12 is a negative control (C). ITAS is the internal PCR control.
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added to PCR buffer [50 mM dNTPs, 1 mg of telomerase
substrate primer, 20 mM Tris/HCl, pH 8.3, 1.5 mM
MgCl2, 63 mM KCl, 1 mM EGTA, 0.1 mg/ml BSA, 2 U of
Taq DNA polymerase (Invitrogen, Paisley, Scotland, UK),
1 mg of alternative complementary (ACX) primer (5V-
GCGCGGCTTACCCTTACCCTTACCCTAACC-3V)] [31].
The reaction mixture was heat-inactivated in a thermal cycler
for 10 minutes at 85jC and 90 seconds at 90jC, then 31
cycles of 94jC for 30 seconds, 50jC for 30 seconds, and
72jC for 90 seconds. Five microliters of PCR product and
2.5 ml of high-density TRIS–borate–EDTA buffer (TBE)
sample dye (Invitrogen) were analyzed on a 12% nondena-
turing polyacrylamide gel in 0.5  TBE running buffer. Local
optimization determined the use of 31 cycles, which did
not lead to false-positive results. Following electrophoresis,
gels were stained for 20 minutes with 1  SYBR Green
(Invitrogen) diluted in running buffer and visualized on a UV
transilluminator. An aliquot of each sample was also heat-
treated (10 minutes, 85jC) before assaying to serve as a
negative control. To control for inhibition of Taq DNA poly-
merase, an internal telomerase assay standard (ITAS;
15 ag) amplified by the same two primers used for the
telomerase activity assay was included in the PCR buffer.
Telomerase activity levels in the biopsies were determined
using GLC4 cells as standard in each assay. Samples were
scored as positive when compared to the GLC4 telomerase
extension products for that assay. Limit of detection was
100 GLC4 cell equivalents. All samples were assayed blind
in duplicate.
Results
Repeatability of Dysplasia Reading
We have established and validated a large database of
comprehensive, closely spaced Barrett’s esophagus biopsy
samples. This enables us to investigate in detail the spatial
distribution of molecular changes. To demonstrate the re-
producibility of the dysplasia scoring, repeat scores are
presented for individual biopsy sites (N = 612) in Table 1.
The overall j score (0.62) represents good agreement.
There is most discrepancy between no dysplasia and indef-
inite for dysplasia, and least between low-grade and high-
grade dysplasia. Merging ‘‘no dysplasia’’ with ‘‘indefinite for
dysplasia’’ creates three categories (no definite dysplasia,
low-grade dysplasia, high-grade dysplasia) with a j score
representing excellent repeatability (0.79). Although
changes suspicious of invasion are often associated with
high-grade dysplasia, we did not identify such changes in
these patients, probably because only five of our patients
were recently diagnosed. The others had been biopsied
previously, and patients with evidence of invasion had been
excluded.
Zonal Distribution of Different Mucosal Types in Barrett’s
Esophagus
In order to investigate the zonal distribution of mucosal
types in Barrett’s esophagus, biopsies were taken for histol-
ogy from the following locations: original squamous mucosa
proximal to the Barrett’s segment, columnar side of the
squamo-columnar junction (Z line), Barrett’s segment every
2 cm, anatomical esophago-gastric junction (defined by the
most proximal gastric folds), gastric corpus, and antrum.
This analysis showed a pronounced proximal-to-distal
zonation of mucosal phenotype in long-segment Barrett’s
esophagus, which was reflected in the probability of detect-
ing different mucosal types at different levels in the Barrett’s
segment. Table 2 is an overview of the data looking at
Barrett’s esophagus by thirds, and Figure 3 is a more
detailed graph of the mean probability for all 32 patients of
different mucosal types being present in Barrett’s esophagus
as a function of anatomical level from the Z line to the most
distal Barrett’s esophagus, excluding the esophago-gastric
junction itself.
Full-thickness squamous epithelium was often detectable
in the upper third of the Barrett’s segment, diminishing in
frequency distally. Superficial squamous islands overlying
glandular mucosa were present less often, but at all levels
without much variation in frequency. Cardiac-like mucosa
occurred at all levels in Barrett’s esophagus, but more often
distally. Oxyntic differentiation hardly occurred above the
lower third. In this location, some biopsies may actually
derive from native gastric mucosa, but there is no doubt that
oxyntic differentiation in an otherwise cardiac-like mucosa
can be found in the true esophagus, confirmed by the
presence of esophageal submucosal glands or their ducts.
In contrast, ‘‘specialized’’ intestinal-type Barrett’s mucosa
was likely to be found at all levels in every case, confirming
its ubiquitous status in Barrett’s esophagus. Equally charac-
teristic in individual cases was the occurrence of several
different mucosal phenotypes at a single anatomical level
(i.e., mucosal zonation in Barrett’s esophagus is present but
does not create horizontal bands of uniform mucosal type,
but a patchwork of mucosal types varying in proportion with
anatomical level).
Dysplasia and Mucosal Phenotype
Our data confirm that dysplasia in Barrett’s esophagus is
especially likely to occur in ‘‘specialized’’ intestinal type
mucosa, and not in other mucosal types [34]. Definite
dysplasia, low- or high-grade, was present at 87 sites
biopsied; in 85 of these, the dysplasia was in continuity with
Table 1. Repeatability of dysplasia grading at 612 individual Barrett’s
esophagus biopsy sites.
Second Reading First Reading
No Dysplasia Indefinite Low Grade High Grade
High grade 0 0 6 21
Low grade 9 6 46 0
Indefinite 20 15 5 0
No dysplasia 469 34 8 0
The same observer was responsible for the first and second readings, which
were performed independently of each other. On the basis of these data,
repeatability of dysplasia grading was regarded as acceptable.
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histologically confirmed ‘‘specialized’’ intestinal type found at
616 sites (14%), and only two dysplastic sites were in
continuity with histologically confirmed cardiac-type mucosa
found at 156 esophageal sites (1.3%) (P < .00001).
Telomerase Activity and Mucosal Phenotype
Telomerase positivity was identifiable at all levels in
Barrett’s esophagus (Table 2), but did fluctuate with location
(Figure 4, a and b; Table 2). Interestingly, TRAP positivity
was most frequent in the upper third of Barrett’s esophagus
(P < .02), fell to a pronounced minimum at the junction of the
upper with the middle third, before rising and falling again as
the esophago-gastric junction is approached.
The original squamous mucosa proximal to Barrett’s
esophagus was almost invariably TRAP+ (31/32, 97%). To
investigate whether the proximal-to-distal gradient of de-
creasing TRAP positivity in the proximal third of Barrett’s
esophagus might reflect a contribution from residual islands
of native squamous epithelium, we looked at TRAP data for
117 biopsies from sites in which ‘‘specialized’’ Barrett’s
mucosa was present. Twenty of 48 biopsies (42%) from
sites where full-thickness squamous epithelium was also
present were TRAP+, against 23/69 (33.3%) from sites in
which squamous epithelium had not been demonstrated.
Similarly, 9 of 21 biopsies (43%) from sites with squamous
islands were TRAP+, against 34/96 (35.4%) without evi-
dence of squamous differentiation. Although there is a trend
toward greater TRAP positivity at Barrett’s sites with residual
squamous mucosa or squamous island differentiation, it
does not reach statistical significance (Fisher’s exact test).
TRAP positivity was unusual in gastric mucosal biopsies
from Barrett’s patients: 1/31 (3%) of gastric body and 2/32
(6%) of gastric antral biopsies. Intestinal metaplasia was also
infrequent in gastric locations [gastric body, 3/32 (9%) and
Table 2. Zonation of mucosal type and telomerase activity (right-hand column) in 32 cases of Barrett’s esophagus.
Location Squamous Mucosa Squamous Islands Specialized Barrett’s Mucosa Cardiac Mucosa Fundic-Like Mucosa TRAP+
Z line 32 10 31 7 0 –
100% 31% 97% 22% 0%
Z line and upper third 32 14 32 10 2 17
100% 44% 100% 31% 6% 53%
Middle third 19 18 32 17 5 8
59% 56% 100% 53% 16% 25%
Lower third 16 15 32 27 23 10
50% 47% 100% 84% 72% 31%
EG junction 7 8 18 23 30 3
22% 25% 56% 72% 94% 10%
Columns show the number and percentage of cases in which different mucosal types were present at various levels including the Z line alone and the upper,
middle, and lower thirds of the Barrett’s segment. The last column shows the frequency of TRAP positivity at the same levels.
Figure 3. Mean probability (expressed as a percentage) for all 32 patients of
different mucosal types being identified in Barrett’s esophagus as a function
of anatomical level, on the vertical axis, from the Z line proximally (top) down
to, but not including, the anatomical esophago-gastric junction distally
(bottom). The grey shaded area in each box shows how often that particular
component is found at that level. The five boxes represent (a) full-thickness
squamous epithelium, (b) squamous islands over glandular mucosa, (c)
‘‘specialized’’ intestinal-type Barrett’s mucosa, (d) cardiac-type mucosa, and
(e) cardio-oxyntic or fundic mucosa.
Figure 4. The left-hand box (a) shows a stacked graph of the number of
telomerase-positive biopsies and the total number of telomerase biopsies as
a function of anatomical level, on the vertical axis, from the Z line proximally
(top) down to, but not including, the anatomical esophago-gastric junction
distally (bottom). Data for all 32 patients with long-segment Barrett’s
esophagus. Horizontal scale is the number of biopsies represented by each
centile. The center graph (b) plots the mean percentage of telomerase
biopsies, which were TRAP+ for all 32 patients with long-segment Barrett’s
esophagus, as a function of anatomical level on the vertical axis. There is
pronounced fluctuation in the percentage of TRAP+ biopsies with anatomical
level. The right-hand box (c) plots the average probability of dysplasia being
present in ‘‘specialized’’ intestinal Barrett’s mucosa as a function of
anatomical level. Data are averaged for the 10 patients with definite dysplasia
and seven patients indefinite for dysplasia. There is no evidence of any
significant proximal-to-distal gradient in dysplasia frequency.
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6/32 (19%)] and gastric intestinal metaplasia was not iden-
tified in the three patients with telomerase-positive gastric
biopsies (Figure 4).
Zonal Distribution of Dysplasia
This was examined in the same way as the zonal distri-
bution of mucosal phenotype. Figure 4c shows the average
probability of dysplasia for 10 cases in which there was
definite dysplasia, and a further seven cases indefinite for
dysplasia. Although some fluctuation in the probability of
dysplasia being present was observed, there was no evi-
dence of any major proximal to distal trend.
Telomerase Activity and Dysplasia
Histological diagnosis of dysplasia is accepted as the
most reliable predictor of cancer risk, yet is not without
difficulties. It is therefore of value to investigate the relation-
ship of any new molecular marker such as telomerase for its
relationship to dysplasia, as this may give an indication of its
potential use in risk assessment as well as basic biological
information on the underlying causes of disease progression.
Table 3 gives an overview of telomerase activity in relation to
the patient’s overall dysplasia status and their dysplasia
status on the occasion of the telomerase endoscopy. Al-
though there is a trend toward more frequent telomerase
positivity with increasing dysplasia, it does not achieve
statistical significance, and some patients with no evidence
of dysplasia had multiple TRAP+ biopsies from the Barrett’s
segment, whereas others with extensive dysplastic change
were TRAP in all biopsies.
Discussion
Barrett’s mucosa is phenotypically complex. ‘‘Specialized’’
intestinal-type Barrett’s mucosa is invariably present in long-
segment Barrett’s esophagus, and the previously reported
association of dysplasia with intestinal Barrett’s mucosa is
very striking in our series [34]. We show also that native
esophageal squamous epithelium, in which consistent ex-
pression of hTR has been described [15–17,35], is also
consistently TRAP+. Esophageal squamous epithelium is
exposed to physical, thermal, and—in the case of Barrett’s
patients—chemical trauma, so this could potentially be an
adaptation to a relatively stressful niche environment, espe-
cially in Barrett’s patients. A study to determine whether
TRAP positivity is likewise ubiquitous in esophageal squa-
mous epithelium of patients without Barrett’s esophagus
would be of value. Although telomerase activity in native
gastric mucosae is rare in Barrett’s patients, esophageal
biopsies in which ‘‘specialized’’ intestinal-type Barrett’s mu-
cosa is characteristic are frequently telomerase-positive.
The absence of obvious zonation of dysplasia in this
study supports the previous observation from relatively
small patient numbers that dysplasia is evenly distributed
along the length of Barrett’s esophagus [36]. The current
recommendation for uniformly distributed endoscopic biop-
sies of the entire Barrett’s segment is therefore supported.
The impressive association between dysplasia and intesti-
nal metaplasia in our series confirms that endoscopic or
molecular markers of the intestinal phenotype might allow
useful biopsy targeting [24].
The low frequency, small size, and unknown telomerase
status of islands of squamous differentiation ‘‘floating’’ over
glandular mucosa make their contribution to TRAP positivity
in our biopsies hard to evaluate, but residual native squa-
mous epithelium may contribute some TRAP+ biopsies in the
proximal third of long Barrett’s segments. More targeted
analysis of telomerase activity of specific cell populations
(e.g., squamous islands versus adjacent Barrett’s mucosa),
by analysis of microdissected samples or in situ methods
could clarify this issue. Similarly, TRAP cardiac and cardio-
oxyntic mucosae could account for the falling proportion of
TRAP+ biopsies in the distal Barrett’s esophagus. This
leaves a steep rise in TRAP positivity beginning at the
junction of the upper third with the middle third of Barrett’s
esophagus to be accounted for (Figure 4b). Unlike native
squamous esophageal mucosa, telomerase activity appears
not to be an intrinsic property of ‘‘specialized’’ intestinal-type
Barrett’s mucosa, as many biopsies from sites where this
mucosa is well represented are TRAP. One possibility is
that it is inducible by local environmental influences, possibly
related to reflux, and susceptibility to such activation could
underlie its powerful association with dysplasia and neopla-
sia in Barrett’s esophagus.
Recently published data suggest a possible mechanism
of telomerase activation in intestinal-type Barrett’s mucosa
[37]. Dietary nitrate, resecreted in saliva, is reduced to nitrite
by oral microorganisms, and swallowed nitrite is further
reduced to nitric oxide (NO) on encountering gastric acid.
Nitrate ingestion leads to a substantial rise in peak nitric
oxide concentration in the esophago-gastric lumen, just
distal to the point at which the luminal pH falls to gastric
levels. Low esophageal pH values could elevate NO levels in
the esophageal lumen, and although there are no published
data for the effect of NO on telomerase activity in Barrett’s,
gastric, or intestinal epithelia, nitric oxide is known to activate
telomerase in endothelial cells [38].
Telomerase activity induced by nitric oxide in intestinal-
type glandular mucosa in Barrett’s patients could confer a
survival advantage accounting for increased goblet cell
Table 3. Telomerase positivity in one or more Barrett’s mucosa biopsies as a
function of worst recorded dysplasia in any biopsy from any endoscopy











in Any Biopsy from
Telomerase Endoscopy
No dysplasia 9/16 12/19
56% 63%
Indefinite for dysplasia 5/6 5/6
83% 83%
Low-grade dysplasia 3/4 3/5
75% 60%
High-grade dysplasia 5/6 2/2
83% 100%
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numbers with age in Barrett’s esophagus [39]. A high fre-
quency of telomerase activity in Barrett’s mucosa of intesti-
nal type could also facilitate survival of clones of cells with
pro-oncogenic mutations. The question immediately sug-
gests itself why there is no obvious relationship between
dysplasia and location in Barrett’s esophagus (as we and
others have shown). One possibility is that abnormal cellular
motility appears often to be a feature of such cellular clones,
identified by a variety of abnormalities such as tetraploidy,
aneuploidy [40], epigenetic changes [41,42], or p16 mutation
[41], all of which may colonize large areas of Barrett’s
mucosa. Such population movement would tend to make
geographical relationships less obvious. Furthermore, the
emergence of dysplasia and telomerase activation are clear-
ly two different things, with multiple causes.
This series shows not only that telomerase-positive mu-
cosa can be present in patients in whom extensive repeated
biopsy showed no dysplasia, but also that patients with
extensive dysplasia can be telomerase-negative. Morales
et al. [16] found a strong association between dysplasia and
telomerase RNA template (hTR) expression, and Lord et al.
[17] showed the same in respect of hTERT mRNA. It may
appear paradoxical, therefore, that such a strong association
does not emerge in our own studies, but we know that most
Barrett’s patients with dysplasia, even high-grade dysplasia,
will never develop esophageal adenocarcinoma, and it fol-
lows that hTR and hTERT, which are overexpressed in most
examples of Barrett’s dysplasia [16,17], cannot identify
Barrett’s esophagus patients most at risk of esophageal
adenocarcinoma. TRAP activity is likely to give a better idea
of telomere maintenance status, and precisely because
telomerase is not active in all Barrett’s dysplasia, it may be
a more effective marker of dysplasia persistence and cancer
risk in Barrett’s esophagus. Some Barrett’s dysplasias dis-
appear over time: perhaps such examples are not protected
from cellular senescence by telomerase activation. Reliable
in situ assays of telomerase activity [43], or simultaneous
morphological and biochemical evaluations of the same
biopsies allowing histology and telomerase activity to be
evaluated simultaneously in the same cells (with microdis-
section, where appropriate) would help to clarify the role of
telomerase activity in the emergence and evolution of
Barrett’s neoplasia.
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